DMACDiaMedica Therapeutics Inc
DMAC
DiaMedica Therapeutics Inc1,554
Mkt Cap
$341.08MVolume
130,988.0052W High
$10.4252W Low
$3.48PE Ratio
-9.06DMAC Fundamentals
Price
$6.33Prev Close
$6.22Open
$6.2050D MA
$7.24Beta
1.18Avg. Volume
232,456.98EPS (Annual)
-$0.6974P/B
6.06Rev/Employee
$0.00$314.32
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Average Rating of "Moderate Buy" from Brokerages
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are covering the company, MarketBeat.com reports. One...
MarketBeat·4d ago
DiaMedica Therapeutics Highlights DM199 Preeclampsia Data, Stroke Interim Catalyst at RedChip Conference
DiaMedica Therapeutics (NASDAQ:DMAC) President and CEO Rick Pauls outlined the company's development programs for its lead candidate, DM199, during a presentation at the RedChip Biotech Investor...
MarketBeat·10d ago
Q1 EPS Estimate for DiaMedica Therapeutics Raised by Analyst
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Free Report) - Stock analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for DiaMedica Therapeutics in a report released on Wednesday, April 1st. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($0.17) per...
MarketBeat·23d ago
HC Wainwright Issues Pessimistic Estimate for DMAC Earnings
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Free Report) - Research analysts at HC Wainwright reduced their FY2029 EPS estimates for DiaMedica Therapeutics in a research note issued to investors on Wednesday, April 1st. HC Wainwright analyst M. Caufield now expects that the company will post earning...
MarketBeat·24d ago
DiaMedica Therapeutics Q4 Earnings Call Highlights
DiaMedica Therapeutics (NASDAQ:DMAC) executives used the company's fiscal 2025 earnings call on Monday to highlight clinical progress for its lead asset DM199 and review an improved year-end cash position following financing activity in 2025.
DM199 mechanism and pipeline focus
President and CEO Ric...
MarketBeat·26d ago
DiaMedica Therapeutics (NASDAQ:DMAC) Posts Earnings Results, Beats Expectations By $0.02 EPS
DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02...
MarketBeat·27d ago
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic...
Business Wire·27d ago
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings
DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday.read more...
Benzinga·28d ago
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Rating of "Moderate Buy" by Brokerages
Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are covering the firm, MarketBeat Ratings...
MarketBeat·29d ago
DiaMedica Therapeutics (DMAC) Projected to Post Earnings on Tuesday
DiaMedica Therapeutics (NASDAQ:DMAC) will be releasing its Q4 2025 earnings on Tuesday, March 31. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-31-diamedica-therapeutics-inc-stock...
MarketBeat·1mo ago
<
1
2
...
>